This month, Maryland’s Attorney General Brian Frosh petitioned the Supreme Court to uphold the “first-in-the-nation” law against drug price-gouging.
This month, Maryland’s Attorney General Brian Frosh petitioned the Supreme Court to uphold the “first-in-the-nation” law against drug price-gouging.The law gives the attorney general the authority to review price information about generic drugs. If the state’s lawyers could show that prices were increasing too steeply, they could seek to order the prices reduced, or issue fines to the drug companies.
The Association for Accessible Medicines (AAM) filed a suit against the state in a US district court in Maryland last year, alleging the bill grants the state “unprecedented powers to regulate the national pharmaceutical market, violating the [US] Constitution and posing harm to vulnerable patient communities.”
In April 2018, a federal appeals court in Maryland ruled that the law, which was passed in 2017, was unconstitutional. In explaining her decision to bar the law from taking effect, Judge Stephanie D. Thacker wrote an opinion stating that “Maryland cannot, even in an effort to protect its consumers from skyrocketing prescription drug costs, impose its preferences in this manner.”
After the decision in late April, Frosh requested that a full federal appeals court rehear the case, explaining that “The resolution of this appeal will substantially affect the responses of state governments to a problem with both fiscal and public health dimensions: the rapidly rising cost of prescription drugs.”
In July, a federal appeals court declined to hear a petition to rehear the case, letting the previous ruling stand.
In reaching the decision to decline to rehear the case, 9 judges voted against, 3 judges voted in favor, and 2 judges did not vote. One of the judges who voted in favor of rehearing the case before the full court, Judge James A. Wynn Jr., wrote that “At a minimum, [the case deserves] the careful deliberation of this entire Court.”
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.